Fingerprint
Dive into the research topics of 'A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically